Craig Webb

NuMedii, Inc. discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies. Its Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The firm translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. The company was founded by Gini Deshpande, Joel Dudley and Atul J. Butte in 2008 and is headquartered in Palo Alto, CA.

NuMedii, Inc. discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies. Its Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The firm translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. The company was founded by Gini Deshpande, Joel Dudley and Atul J. Butte in 2008 and is headquartered in Palo Alto, CA.

NuMedii, Inc. discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies. Its Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The firm translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. The company was founded by Gini Deshpande, Joel Dudley and Atul J. Butte in 2008 and is headquartered in Palo Alto, CA.

NuMedii, Inc. discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies. Its Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The firm translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. The company was founded by Gini Deshpande, Joel Dudley and Atul J. Butte in 2008 and is headquartered in Palo Alto, CA.

NuMedii, Inc. discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies. Its Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The firm translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. The company was founded by Gini Deshpande, Joel Dudley and Atul J. Butte in 2008 and is headquartered in Palo Alto, CA.